BRIEF-FDA Approves Linzess Capsules For Children Aged 7 And Older With IBS With Constipation

Reuters

Nov 06, 2025

Nov 5 (Reuters) - FDA:

FDA: APPROVED LINZESS (LINACLOTIDE) CAPSULES FOR PEDIATRIC PATIENTS 7 YEARS AND OLDER WITH IRRITABLE BOWEL SYNDROME WITH CONSTIPATION
FDA: LINZESS RECOMMENDED DOSAGE FOR PEDIATRIC PATIENTS 7 YEARS AND OLDER WITH IBS-C IS 145 MCG ORALLY ONCE DAILY

Further company coverage: IRWD.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2581087117"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2581087117\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2581087117?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-06 02:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2581087117","market":"fut","top_or_hot":-1,"title":"BRIEF-FDA Approves Linzess Capsules For Children Aged 7 And Older With IBS With Constipation","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-FDA Approves Linzess Capsules For Children Aged 7 And Older With IBS With Constipation</title></head><body><p><span>Nov 5 (Reuters)</span><span> - </span>FDA: </p><ul><li><p>FDA: APPROVED LINZESS (LINACLOTIDE) CAPSULES FOR PEDIATRIC PATIENTS 7 YEARS AND OLDER WITH IRRITABLE BOWEL SYNDROME WITH CONSTIPATION</p></li><li><p>FDA: LINZESS RECOMMENDED DOSAGE FOR PEDIATRIC PATIENTS 7 YEARS AND OLDER WITH IBS-C IS 145 MCG ORALLY ONCE DAILY</p></li></ul><p>Further company coverage: <span>IRWD.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-FDA Approves Linzess Capsules For Children Aged 7 And Older With IBS With Constipation</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-FDA Approves Linzess Capsules For Children Aged 7 And Older With IBS With Constipation\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-06 02:31</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-FDA Approves Linzess Capsules For Children Aged 7 And Older With IBS With Constipation</title></head><body><p><span>Nov 5 (Reuters)</span><span> - </span>FDA: </p><ul><li><p>FDA: APPROVED LINZESS (LINACLOTIDE) CAPSULES FOR PEDIATRIC PATIENTS 7 YEARS AND OLDER WITH IRRITABLE BOWEL SYNDROME WITH CONSTIPATION</p></li><li><p>FDA: LINZESS RECOMMENDED DOSAGE FOR PEDIATRIC PATIENTS 7 YEARS AND OLDER WITH IBS-C IS 145 MCG ORALLY ONCE DAILY</p></li></ul><p>Further company coverage: <span>IRWD.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IRWD","symbol_name":"Ironwood医药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251105:nFWN3WH1IK:1","article_id":"2581087117","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2581087117","pubTimestamp":1762367493,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-FDA Approves Linzess Capsules For Children Aged 7 And Older With IBS With ConstipationNov 5  - FDA: FDA: APPROVED LINZESS  CAPSULES FOR PEDIATRIC PATIENTS 7 YEARS AND OLDER WITH IRRITABLE BOWEL SYNDROME WITH CONSTIPATIONFDA: LINZESS RECOMMENDED DOSAGE FOR PEDIATRIC PATIENTS 7 YEARS AND OLDER WITH IBS-C IS 145 MCG ORALLY ONCE DAILYFurther company coverage: IRWD.O ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IRWD":"Ironwood医药","BK4139":"生物科技"},"translate_title":"简介-FDA批准Linzess胶囊用于7岁及以上IBS伴便秘儿童","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IRWD":0.9},"content_text":"BRIEF-FDA Approves Linzess Capsules For Children Aged 7 And Older With IBS With ConstipationNov 5 (Reuters) - FDA: FDA: APPROVED LINZESS (LINACLOTIDE) CAPSULES FOR PEDIATRIC PATIENTS 7 YEARS AND OLDER WITH IRRITABLE BOWEL SYNDROME WITH CONSTIPATIONFDA: LINZESS RECOMMENDED DOSAGE FOR PEDIATRIC PATIENTS 7 YEARS AND OLDER WITH IBS-C IS 145 MCG ORALLY ONCE DAILYFurther company coverage: IRWD.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}